Cullinan Net Interest Income vs Total Other Income Expense Net Analysis
CGEM Stock | USD 23.50 0.71 3.12% |
Cullinan Oncology financial indicator trend analysis is way more than just evaluating Cullinan Oncology LLC prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cullinan Oncology LLC is a good investment. Please check the relationship between Cullinan Oncology Net Interest Income and its Total Other Income Expense Net accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.
Net Interest Income vs Total Other Income Expense Net
Net Interest Income vs Total Other Income Expense Net Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cullinan Oncology LLC Net Interest Income account and Total Other Income Expense Net. At this time, the significance of the direction appears to have totally related.
The correlation between Cullinan Oncology's Net Interest Income and Total Other Income Expense Net is 1.0. Overlapping area represents the amount of variation of Net Interest Income that can explain the historical movement of Total Other Income Expense Net in the same time period over historical financial statements of Cullinan Oncology LLC, assuming nothing else is changed. The correlation between historical values of Cullinan Oncology's Net Interest Income and Total Other Income Expense Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Interest Income of Cullinan Oncology LLC are associated (or correlated) with its Total Other Income Expense Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Other Income Expense Net has no effect on the direction of Net Interest Income i.e., Cullinan Oncology's Net Interest Income and Total Other Income Expense Net go up and down completely randomly.
Correlation Coefficient | 1.0 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Total Other Income Expense Net
Most indicators from Cullinan Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cullinan Oncology LLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. As of the 3rd of June 2024, Selling General Administrative is likely to grow to about 44.6 M, though Tax Provision is likely to grow to (13.4 M).
2023 | 2024 (projected) | Non Recurring | 183.9K | 97.2K | Research Development | 148.2M | 155.6M |
Cullinan Oncology fundamental ratios Correlations
Click cells to compare fundamentals
Cullinan Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cullinan Oncology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 100.5M | 214.7M | 437.2M | 561.1M | 485.1M | 509.4M | |
Total Current Liabilities | 2.5M | 14.3M | 11.7M | 22.5M | 28.1M | 29.5M | |
Accounts Payable | 934K | 9.7M | 3.2M | 2.7M | 2.5M | 2.0M | |
Other Current Assets | 1.5M | 2.1M | 6.1M | 7.2M | 13.1M | 13.8M | |
Total Liab | 140.4M | 291.0M | 11.8M | 26.1M | 31.2M | 56.0M | |
Total Stockholder Equity | (40.8M) | (77.6M) | 422.6M | 535.0M | 453.7M | 476.4M | |
Net Tangible Assets | (40.8M) | (77.6M) | 425.0M | 535.0M | 615.3M | 646.0M | |
Retained Earnings | (41.5M) | (93.3M) | (158.9M) | (47.7M) | (200.9M) | (190.8M) | |
Cash | 63.3M | 168.2M | 430.9M | 550.1M | 98.4M | 147.9M | |
Total Current Assets | 100.1M | 212.3M | 296.6M | 474.5M | 480.2M | 504.2M | |
Other Current Liab | 1.6M | 4.6M | 8.6M | 18.2M | 24.2M | 25.4M | |
Property Plant And Equipment Net | 182K | 130K | 77K | 5.3M | 3.5M | 3.7M | |
Net Debt | (63.3M) | (168.2M) | (430.9M) | (544.9M) | (94.8M) | (99.6M) | |
Non Current Assets Total | 370K | 2.4M | 140.6M | 86.6M | 4.9M | 4.7M | |
Cash And Short Term Investments | 98.6M | 210.2M | 430.9M | 550.1M | 467.1M | 328.3M | |
Short Term Investments | 35.4M | 42.0M | 230.7M | 311.1M | 368.6M | 387.1M | |
Liabilities And Stockholders Equity | 100.5M | 214.7M | 434.8M | 561.1M | 485.1M | 335.6M | |
Non Current Liabilities Total | 137.8M | 276.7M | 65K | 3.6M | 3.1M | 2.9M | |
Other Stockholder Equity | (137.0M) | (261.0M) | 582.3M | 585.3M | 654.7M | 687.4M | |
Net Invested Capital | (40.8M) | (77.6M) | 425.0M | 535.2M | 453.7M | 233.7M | |
Property Plant And Equipment Gross | 182K | 130K | 309K | 5.4M | 3.9M | 4.1M | |
Accumulated Other Comprehensive Income | (4K) | (2K) | (838K) | (2.6M) | (129K) | (135.5K) | |
Net Working Capital | 97.6M | 198.0M | 284.8M | 452.0M | 452.1M | 278.2M | |
Property Plant Equipment | 182K | 130K | 77K | 1.2M | 1.4M | 1.4M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Cullinan Oncology LLC using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Cullinan Oncology LLC information on this page should be used as a complementary analysis to other Cullinan Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Cullinan Stock analysis
When running Cullinan Oncology's price analysis, check to measure Cullinan Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cullinan Oncology is operating at the current time. Most of Cullinan Oncology's value examination focuses on studying past and present price action to predict the probability of Cullinan Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cullinan Oncology's price. Additionally, you may evaluate how the addition of Cullinan Oncology to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Cullinan Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.13) | Return On Assets (0.22) | Return On Equity (0.29) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.